circRNA basic information
circBase ID: hsa_circ_0005320
Name: hsa_circ_SEPT9
Synonym: -
Host Gene: SEPT9
Genomic location(hg19): chr17:75398140-75398785:+
Genomic location(hg38): chr17:77402058-77402703:+
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0005494
MONDO name: triple-negative breast carcinoma
Disease details: triple-negative breast cancer
Disease DO ID:
 0060081
Disease MeSH ID:
 D064726
Disease NCIt ID:
 C71732
Disease ICD11 ID:
 -
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

TNBC tissues; paracancerous tissues; adjacent normal tissues
Cell lines:

MDA-MB-231; BT-549; MDA-MB-468; MDA-MB-453; SUM-159; MCF-10A; 293T; 293
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: LIF, E2F1, EIF4A3, STAT3
Associated microRNA: miR-637
Biological function: Promotes proliferation, migration and invasion; promotes tumor growth and metastasis; induces apoptosis and autophagy when knocked down (tumor-promoting role in TNBC).
Molecular mechanism: circSEPT9 acts as a ceRNA by sponging miR-637 to up-regulate LIF and activate LIF/STAT3 signaling; its biogenesis/expression is promoted by E2F1 (via SEPT9 promoter) and EIF4A3 (binding SEPT9 pre-mRNA).
Biological pathway or process:

proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); autophagy (inhibits); metastasis (promotes); JAK/STAT (promotes); ceRNA regulation (promotes)
Detected method:
Q
H
S
Validation methods:

RNA-seq; RT-qPCR; Clinical Sample Validation; ISH (In Situ Hybridization); ROC Analysis; Survival Analysis; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); ChIP / ChIP-seq; Transfection; CCK8; EdU Staining; Colony Formation Assay; Wound Healing Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; TUNEL; IF (Immunofluorescence); IHC (Immunohistochemistry); Western Blot; In Vivo Animal Model; H&E Staining; Cohort Study
Clinical significance:

High circSEPT9 expression is positively correlated with advanced clinical stage and predicts poor prognosis; circSEPT9 shows diagnostic value by ROC analysis and is an independent predictor of poor prognosis in TNBC.
Description:

circSEPT9 (hsa_circ_0005320), derived from SEPT9, is up-regulated in TNBC and promotes proliferation, migration/invasion, tumor growth and metastasis. It mainly localizes to the cytoplasm and functions as a ceRNA by sponging miR-637 to increase LIF and activate LIF/STAT3 signaling; E2F1 and EIF4A3 promote its biogenesis/expression. High circSEPT9 expression correlates with advanced stage and poor overall survival, supporting its prognostic/diagnostic potential.
Confidence score:

0.8972
Other information
Title:

The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.

Journal: Molecular cancer
Published: 2020
PubMed ID: 32264877
Study type:

combined biological and clinical study
Data availability: The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Code availability: -